Literature DB >> 31767718

Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST).

Jason M Pogue1, Ronald N Jones2, John S Bradley3,4, David R Andes5, Sujata M Bhavnani6, George L Drusano7, Michael N Dudley8, Robert K Flamm9, Keith A Rodvold10, Paul G Ambrose6.   

Abstract

The polymyxins are important agents for carbapenem-resistant Gram-negative bacilli. The United States Committee on Antimicrobial Susceptibility Testing breakpoint recommendations for colistin and polymyxin B are that isolates of Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae are considered susceptible at MIC values of ≤2 mg/liter. These recommendations are contingent upon dosing and testing strategies that are described in this commentary. Importantly, these recommendations are not applicable to lower respiratory tract infections, for which we recommend no breakpoints. Furthermore, there is no breakpoint recommendation for polymyxin B for lower urinary tract infections.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  USCAST; breakpoints; colistin; polymyxin B; polymyxins

Mesh：

Substances：

Year:  2020        PMID： 31767718      PMCID： PMC6985752          DOI： 10.1128/AAC.01495-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  61 in total

1.  Colistin resistance gene mcr-1 in extended-spectrum β-lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany.

Authors:  Linda Falgenhauer; Said-Elias Waezsada; Yancheng Yao; Can Imirzalioglu; Annemarie Käsbohrer; Uwe Roesler; Geovana Brenner Michael; Stefan Schwarz; Guido Werner; Lothar Kreienbrock; Trinad Chakraborty
Journal:  Lancet Infect Dis       Date:  2016-01-08       Impact factor: 25.071

2.  Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections.

Authors:  Rujipas Sirijatuphat; Visanu Thamlikitkul
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

3.  The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study.

Authors:  Yael Dishon Benattar; Muna Omar; Oren Zusman; Dafna Yahav; Yael Zak-Doron; Sergey Altunin; Michal Elbaz; Vered Daitch; Michal Granot; Leonard Leibovici; Mical Paul
Journal:  Clin Infect Dis       Date:  2016-10-06       Impact factor: 9.079

4.  Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.

Authors:  Yaakov Dickstein; Jonathan Lellouche; Maayan Ben Dalak Amar; David Schwartz; Amir Nutman; Vered Daitch; Dafna Yahav; Leonard Leibovici; Anna Skiada; Anastasia Antoniadou; George L Daikos; Roberto Andini; Rosa Zampino; Emanuele Durante-Mangoni; Johan W Mouton; Lena E Friberg; Yael Dishon Benattar; Roni Bitterman; Ami Neuberger; Yehuda Carmeli; Mical Paul
Journal:  Clin Infect Dis       Date:  2019-08-16       Impact factor: 9.079

5.  Dosing guidance for intravenous colistin in critically-ill patients.

Authors:  Roger L Nation; Samira M Garonzik; Visanu Thamlikitkul; Evangelos J Giamarellos-Bourboulis; Alan Forrest; David L Paterson; Jian Li; Fernanda P Silveira
Journal:  Clin Infect Dis       Date:  2016-12-23       Impact factor: 9.079

6.  Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.

Authors:  A C Gales; A O Reis; R N Jones
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

7.  Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.

Authors:  George L Daikos; Sophia Tsaousi; Leonidas S Tzouvelekis; Ioannis Anyfantis; Mina Psichogiou; Athina Argyropoulou; Ioanna Stefanou; Vana Sypsa; Vivi Miriagou; Martha Nepka; Sarah Georgiadou; Antonis Markogiannakis; Dimitris Goukos; Athanasios Skoutelis
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

8.  Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).

Authors:  A C Gales; R N Jones; H S Sader
Journal:  Clin Microbiol Infect       Date:  2006-04       Impact factor: 8.067

9.  Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study.

Authors:  Luisa Sorlí; Sonia Luque; Santiago Grau; Núria Berenguer; Concepción Segura; María Milagro Montero; Francisco Alvarez-Lerma; Hernando Knobel; Natividad Benito; Juan P Horcajada
Journal:  BMC Infect Dis       Date:  2013-08-19       Impact factor: 3.090

10.  Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa.

Authors:  Bin Cai; Roger Echols; Glenn Magee; Juan Camilo Arjona Ferreira; Gareth Morgan; Mari Ariyasu; Takuko Sawada; Tsutae Den Nagata
Journal:  Open Forum Infect Dis       Date:  2017-08-16       Impact factor: 3.835
View more
  7 in total

1.  Plasma concentrations of Colistin sulfate in a patient with septic shock on extracorporeal membrane oxygenation and continuous renal replacement therapy: a case report.

Authors:  Danyang Peng; Fan Zhang; Pin Lv; Yinyin Chen; Jianxu Yang; Wenliang Zhu; Shichao Zhu; Huanzhang Shao
Journal:  Ann Transl Med       Date:  2022-05

2.  Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Carbapenem-Resistant Gram-Negative Bacterial Infections Among Chinese Children.

Authors:  Xuedong Jia; Zhao Yin; Wan Zhang; Conghui Guo; Shuzhang Du; Xiaojian Zhang
Journal:  Front Pharmacol       Date:  2022-05-27       Impact factor: 5.988

Review 3.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 4.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

Review 5.  Global colistin use: a review of the emergence of resistant Enterobacterales and the impact on their genetic basis.

Authors:  Ulrike Binsker; Annemarie Käsbohrer; Jens A Hammerl
Journal:  FEMS Microbiol Rev       Date:  2022-02-09       Impact factor: 16.408

6.  Manual Reading of Sensititre Broth Microdilution System Panels Improves Accuracy of Susceptibility Reporting for Polymyxin Antibiotics.

Authors:  Michelle M Bellerose; Andrew E Clark; Jung-Ho Youn; Rebecca A Weingarten; Chelsea M Crooks; John P Dekker; Karen M Frank
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

7.  Comparative genomic analyses of Polymyxin-resistant Enterobacteriaceae strains from China.

Authors:  Zhien He; Yongqiang Yang; Wei Li; Xiaoling Ma; Changfeng Zhang; Jingxiang Zhang; Baolin Sun; Tao Ding; Guo-Bao Tian
Journal:  BMC Genomics       Date:  2022-01-31       Impact factor: 3.969
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.